Dyrskjøt L. .2023 .. Bladder Cancer.” Nature Reviews Disease Primers, 9(1) : .
Lobo N. .2022 .Epidemiology, Screening and Prevention of Bladder Cancer. European Urology Oncology, 10(2022) : 628-639.
Tran L. . .. Advances in Bladder Cancer Biology and Therapy.” Nature Reviews Cancer, 21(2021) : 104-121.
Olislagers M. . .Molecular Biomarkers of Progression in Non-Muscle-Invasive Bladder Cancer-Beyond Conventional Risk Stratification. Nature Reviews Urology, 22(2025) : 75-91.
Bell S.D. .2025 .Squamous Cell Bladder Cancer: A Rare Histological Variant with a Demand for Modern Cancer Therapeutics. ” Cancers, 17(2) : .
Dolgasheva D.S. .2024 .Human Papillomavirus and Bladder Cancer: Literature Review and Meta-Analysis. African Journal of Urology, 30(1) : .
Devlies W. .2023 .The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria. ” European Urology Focus, 08(2024) : 115-122.
Chou W.H.,Investigations Original .2021 .Cyclophosphamide-Associated Bladder Cancers and Considerations for Survivorship Care. , : .
Abbas N.F. .2023 .Uncovering the Epidemiology of Bladder Cancer in the Arab World. Asian Journal of Urology, 10(2024) : 406-422.
Saginala K. .2020 .. Epidemiology of Bladder Cancer.” Medical Sciences, 8(1) : .
Siegel R.L. .2021 .A Cancer Journal for Clinicians. Cancer Statistics, 71(2021) : 7-33.
Sung H. .2020 .A Cancer Journal for Clinicians. Global Cancer Statistics, 71(2021) : 209-249.
Mushtaq J. .2019 .. Bladder Cancer.” Surgery (Oxford), 07(2019) : 529-537.
Chang S.S. .2016 .Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer. The Journal of Urology, 06(2016) : 1021-1029.
Ma .2023 .“Long-Term Recurrence Rates of Low-Risk NonMuscle-Invasive Bladder Cancer. European Urology Focus, 06(2024) : 189-196.
Thomas J. .2024 .. Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer.” Clinical Genitourinary Cancer, 102286(1) : .
Oszczudlowski M.,Dobruch J. .2018 .Prediction of Progression to Muscle-Invasive Disease. ” Translational Andrology and Urology, 06(4) : .
Filon M.,Schmidt B. .2025 .New Treatment Options for NonMuscle-Invasive Bladder Cancer.” ASCO Educational Book. , 45(2) : .
Teoh J.Y.C. . .Recurrence Mechanisms of Non-MuscleInvasive Bladder Cancer. Nature Reviews Urology, 19(2022) : 280-294.
Bryan R.T. . .Mechanisms of Recurrence of Ta/T1 Bladder Cancer.” Annals of the Royal College of Surgeons of England. , 92(2010) : 519-524.
Liu W. .2024 .Recurrence and Prevention Strategies for NonMuscle-Invasive Bladder Cancer: A Comprehensive Review. Asian Journal of Urology, 12 : .
Wiesen B. .2025 .Updated Review on Novel Therapies and Ongoing Clinical Trials for High-Risk Non-Muscle Invasive Bladder Cancer. , 1519428 : .
Whelan P. “ .2007 .The Treatment of Non-Muscle-Invasive Bladder Cancer with Intravesical Chemotherapy and Immunotherapy. European Urology Supplements, 01(2007) : 568-571.
Scilipoti P.,Meta-Analysis P. .2024 .The Role of Mitomycin C in IntermediateRisk Non-Muscle-Invasive Bladder Cancer: A Systematic Review. ” European Urology Oncology, 06 : .
Zargar H. .2014 .Optimizing Intravesical Mitomycin C Therapy in Non-Muscle-Invasive Bladder Cancer. Nature Reviews Urology, 52(2014) : 220-230.
Gederaas O.A. .2014 .Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Translational Oncology, 10(6) : .
.2022 .Effect of Intravesical Mitomycin Compared with Gemcitabine on the Treatment of Non-Muscle Invasive Bladder Cancer: A Meta-Analysis.” Actas Urológicas Españolas (English Edition). , 12(2023) : 92-98.
Shao .2022 .Clinical Efficacy of Intravesical Gemcitabine Combined with Ubenimex in Patients with Non-MuscleInvasive Bladder Carcinoma. Pakistan Journal of Medical Sciences, 38(5) : .
Du W. .2024 .UPP1 Enhances Bladder Cancer Progression and Gemcitabine Resistance through AKT. International Journal of Biological Sciences, 20(4) : .
Stadler W.M. .1997 .Phase II Study of Single-Agent Gemcitabine in Previously Untreated Patients with Metastatic Urothelial Cancer. ” Journal of Clinical Oncology, 15(11) : 3394-3398.
Beutel A.K.,Halbrook C.J. .2022 .Barriers and Opportunities for Gemcitabine in Pancreatic Cancer Therapy. American Journal of Physiology-Cell Physiology, 324(2023) : C540-C552.
Bastiancich C. .2017 .. Gemcitabine and Glioblastoma: Challenges and Current Perspectives.” Drug Discovery Today, 10(2018) : 416-423.
Prasanna T. .2017 .Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for Non-Muscle Invasive Bladder Cancer. , 00260 : .
Li R. .2020 .Intravesical Gemcitabine versus Mitomycin for Non-Muscle Invasive Bladder Cancer. BMC Urology, 20 : 1-8.
Gupta A. . .Obesity Is Independently Associated with Increased Risk of Hepatocellular Cancer-Related Mortality. American Journal of Clinical Oncology, 41(2018) : 0000000000-000388.
Xiaohong Z. .2015 .Clinical Effect of Antineoplastic Drug Perfusion in Preventing Postoperative Recurrence of Superficial Bladder Cancer. ” Journal of Chinese Physician, 17 : 1043-1045.
Lin T.,Sun L. .2016 .Comparison of the Efficacy of Different Chemotherapy Drugs in Preventing Postoperative Recurrence of Superficial Bladder Cancer. China Foreign Medical Treatment, 35 : 118-119.
Sun S. .2016 .Comparison of Intravesical Perfusion of Gemcitabine and Mitomycin after Non-Muscle Invasive Bladder Cancer. ” Journal of Medical Theory and Practice, 29 : 3238-3239.
Dong X. .2017 .Curative Effect Analysis of Different Chemotherapeutics at Intravesical Instillation after TUR-Bt. Zhejiang Journal of Traumatic Surgery, 22 : 109-110.
Addeo R. .2008 .Randomized Phase III Trial on Gemcitabine versus Mitomycin in Recurrent Superficial Bladder Cancer. ” Journal of Clinical Oncology, 20(2010) : 543-548.
Alam S. . .Intravesical Gemcitabine and Mitomycin C Chemotherapy in Non-Muscle Invasive Transitional Cell Carcinoma. Bangladesh Journal of Urology, 22(2019) : 50071-29.
Chaaya Abou,C. Abou .2024 .Comparing Efficacy and Safety of InHouse Gemcitabine to Mitomycin for Bladder Instillation. The French Journal of Urology, 102699(13) : .
Shelley M.D. .2011 .Intravesical Gemcitabine Therapy for Non-Muscle Invasive Bladder Cancer. , 10880(2012) : 1464-410X.
Messing E.M. .2018 .Effect of Intravesical Gemcitabine vs Saline after Resection of Low-Grade Bladder Cancer. ” JAMA, 4657(18) : 1880-1888.
Dalbagni G. .2005 .Phase II Trial of Intravesical Gemcitabine in BCG-Refractory Bladder Cancer. ” Journal of Clinical Oncology, 05(18) : 2729-2734.
Bartoletti R. .2005 .Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma. ” Urology, 04(2005) : 726-731.
Matloubieh J.E. .2024 .Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine. ” Cancers, 16(24) : .
Cockerill P.A. . .Intravesical Gemcitabine Combined with Mitomycin C as Salvage Treatment. , 117(2016) : 456-462.
Lightfoot A.J. .2014 .Sequential Intravesical Gemcitabine and Mitomycin C for Bladder Cancer. Urologic Oncology: Seminars and Original Investigations, : .
Zeng J. .2023 .Gemcitabine as First-Line Therapy for HighGrade Non-Muscle Invasive Bladder Cancer. Translational Andrology and Urology, 12(6) : .